- Liz Highleyman | 08 May 2014
An interferon-free combination of
sofosbuvir (Sovaldi) plus ribavirin
taken for up to 24 weeks led to sustained virological response in 70% of liver
transplant recipients with hepatitis C virus (HCV) recurrence, according to ...
- Liz Highleyman | 06 May 2014
Curative treatment that eliminates
hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most concerning
symptoms associated with chronic hepatitis C, according to research presented at the ...
- Liz Highleyman | 02 May 2014
A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of
people with hard-to-treat hepatitis C virus genotype 4, though treatment for
only 12 weeks was not as effective, according to a ...
- Keith Alcorn | 23 April 2014
A three-drug combination of direct-acting antivirals
developed by AbbVie cured hepatitis C genotype 1 infection in 96% of transplant
recipients with recurrent hepatitis C in a small phase II study reported earlier ...
- Liz Highleyman | 23 April 2014
Hepatitis C treatment using
sofosbuvir (Sovaldi) is highly
effective even for people with multiple factors traditionally associated with
poor response. Having four or more negative predictive factors, however, raises
the risk of post-treatment relapse, ...
- Liz Highleyman | 17 April 2014
A new experimental NS5A
inhibitor, GS-5816, was shown to be safe and effective when used in an
interferon- and ribavirin-free dual regimen with sofosbuvir (Sovaldi) for people with hepatitis C
genotypes 1 through ...
- Keith Alcorn | 17 April 2014
A combination of two direct-acting antivirals developed by
Bristol-Myers Squibb (BMS) cured 90% of previously untreated people with genotype 1b hepatitis C
infection in 24 weeks, without the need for pegylated interferon ...
- Liz Highleyman | 16 April 2014
Sofosbuvir plus ribavirin is a
safe option that can lead to sustained response in people with advanced liver
disease including those with decompensated cirrhosis and portal hypertension,
and people who experience severe hepatitis ...
- Liz Highleyman | 16 April 2014
Adding pegylated interferon to
entecavir (Baraclude) led to greater
hepatitis B virus (HBV) viral load decline and higher likelihood of serological
response in people with HBeAg-positive chronic hepatitis B, as did added
interferon after ...
- Keith Alcorn | 15 April 2014
The largest study of new direct-acting antivirals yet
conducted in people with hepatitis C genotype 1 who have compensated cirrhosis has
shown that it is possible to cure between 92 and 96% ...
- Keith Alcorn | 14 April 2014
A combination of two direct-acting antivirals developed by AbbVie cured
100% of previously untreated patients with hepatitis C genotype 4 infection
when used with ribavirin, Christophe Hézode reported on Friday at the ...
- Liz Highleyman | 14 April 2014
A co-formulation of sofosbuvir and
ledipasvir taken for as little as eight to twelve weeks produced high sustained response
rates across the board for participants in the phase 3 ION trials, including ...
- Liz Highleyman | 14 April 2014
A 12-week oral regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) without pegylated interferon or
ribavirin led to sustained virological response in 93% of people with genotype 1 hepatitis
C virus (HCV) with ...
- Keith Alcorn | 11 April 2014
The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with ...
- Liz Highleyman | 11 April 2014
Treatment for 12 weeks with a
co-formulation of sofosbuvir and ledipasvir led to sustained response for all
participants with HIV and HCV co-infection who had genotype 1 hepatitis C virus (HCV) followed ...
- Liz Highleyman | 11 April 2014
A co-formulation of sofosbuvir
and ledipasvir successfully treated a variety of difficult-to-treat patient
populations including people with hepatitis C virus (HCV) genotype 3, people
with decompensated cirrhosis and people who were not cured ...
- Keith Alcorn | 10 April 2014
Almost 90% of European patients who had relapsed after previous
treatment with pegylated interferon and ribavirin were cured of hepatitis C
after 24 weeks of treatment with the protease inhibitor simeprevir (Olysio) ...
- Keith Alcorn | 10 April 2014
A 12-week course of three direct-acting antivirals developed by AbbVie,
plus ribavirin, cured 96.3% of treatment-experienced patients with hepatitis C
genotype 1 infection, Professor Stefan Zeuzem of the JW
Goethe University Hospital, Frankfurt, ...
- Keith Alcorn | 09 April 2014
The World Health Organization has issued global
treatment guidelines for hepatitis C, strongly recommending the use of the
new direct-acting antivirals sofosbuvir (Sovaldi)
with ribavirin for genotypes 1, 2, 3 and 4 or ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...